Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: Despite multiple drugs available, a large proportion of patients with generalized anxiety disorder (GAD) do not show adequate response and remission. Thus, additional novel pharmacological agents are needed to increase treatment option for GAD. We aimed to investigate efficacy and safety of agomelatine in the treatment of GAD by conducting a meta-analysis. Methods: An extensive search of multiple databases and clinical trial registries were conducted. Mean change in total scores on Hamilton Anxiety Rating Scale (HAM-A) from baseline to endpoint was our primary outcome measure. Secondary efficacy measures included response and remission rates, as defined by a 50% or greater reduction in HAM-A total scores and a score of 7 or less in HAM-A total scores at study endpoint respectively. Results: Four published double blinded, randomized, placebo-controlled trials were included in this meta-analysis. Agomelatine more significantly (standardized mean difference = −0.56, p = 0.004) improved HAM-A total scores than placebo. The odds ratios (ORs) of agomelatine over placebo for response and remission rates were 3.75 (p ＜ 0.00001) and 2.74 (p ＜ 0.00001), respectively. Agomelatine was generally well tolerated with insignificance in dropout rate, somnolence, headache, nasopharyngitis, and dizziness compared with placebo. However, agomelatine showed significantly higher incidence of liver function increment (OR = 3.13, p = 0.01) and nausea (OR = 3.27, p = 0.02). Conclusion: We showed that agomelatine may be another treatment option in patients with GAD. However, the results should be interpreted and translated into clinical practice with caution because the meta-analysis was based on limited numbers of clinical trials.
Abstract
Objective: Despite multiple drugs available, a large proportion of patients with generalized anxiety disorder (GAD) do not show adequate response and remission. Thus, additional novel pharmacological agents are needed to increase treatment option for GAD. We aimed to investigate efficacy and safety of agomelatine in the treatment of GAD by conducting a meta-analysis. Methods: An extensive search of multiple databases and clinical trial registries were conducted. Mean change in total scores on Hamilton Anxiety Rating Scale (HAM-A) from baseline to endpoint was our primary outcome measure. Secondary efficacy measures included response and remission rates, as defined by a 50% or greater reduction in HAM-A total scores and a score of 7 or less in HAM-A total scores at study endpoint respectively. Results: Four published double blinded, randomized, placebo-controlled trials were included in this meta-analysis. Agomelatine more significantly (standardized mean difference = −0.56, p = 0.004) improved HAM-A total scores than placebo. The odds ratios (ORs) of agomelatine over placebo for response and remission rates were 3.75 (p ＜ 0.00001) and 2.74 (p ＜ 0.00001), respectively. Agomelatine was generally well tolerated with insignificance in dropout rate, somnolence, headache, nasopharyngitis, and dizziness compared with placebo. However, agomelatine showed significantly higher incidence of liver function increment (OR = 3.13, p = 0.01) and nausea (OR = 3.27, p = 0.02). Conclusion: We showed that agomelatine may be another treatment option in patients with GAD. However, the results should be interpreted and translated into clinical practice with caution because the meta-analysis was based on limited numbers of clinical trials.
참고문헌 (40)
- Wittchen HU, "Size and burden of mental disorders in Europe : a critical review and appraisal of 27 studies", Eur Neuropsychopharmacol, 15, pp.357~376 (2005)
- Ebru Fındıklı, "The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug Naïve, First Episode, Non-Smoker Generalized Anxiety Disorder Patients", Clinical Psychopharmacology and Neuroscience, 16(1), pp.88~94 (2018), 대한정신약물학회[DOI]
- Hoffman DL, "Human and economic burden of generalized anxiety disorder", Depress Anxiety, 25, pp.72~90 (2008)
- Wittchen HU, "Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey", Int Clin Psychopharmacol, 15, pp.319~328 (2000)
- Li-Min Xin, "Risk Factors for Anxiety in Major Depressive Disorder Patients", Clinical Psychopharmacology and Neuroscience, 13(3), pp.263~268 (2015), 대한정신약물학회
- Strawn JR, "Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients : an evidence-based treatment review", Expert Opin Pharmacother, 19, pp.1057~1070 (2018)
- Alessandro Serretti, "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants", Clinical Psychopharmacology and Neuroscience, 16(1), pp.1~6 (2018), 대한정신약물학회[DOI]
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- Buoli M, "New approaches to the pharmacological management of generalized anxiety disorder", Expert Opin Pharmacother, 14, pp.175~184 (2013)
- Wittchen HU, "Generalized anxiety disorder : prevalence, burden, and cost to society", Depress Anxiety, 16, pp.162~171 (2002)
- Norman TR, "Agomelatine for depression : expanding the horizons", Expert Opin Pharmacother, 20, pp.647~656 (2019)
- Papp M, "Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety", Behav Pharmacol, 17, pp.9~18 (2006)
- Tuma J, "Anxiolytic-like action of the antidepressant agomelatine(S 20098)after a social defeat requires the integrity of the SCN", Eur Neuropsychopharmacol, 15, pp.545~555 (2005)
- Conboy L, "The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule(NCAM)expression in the hippocampus of rats", Int J Neuropsychopharmacol, 12, pp.329~341 (2009)
- Millan MJ, "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade", Psychopharmacology(Berl), 177, pp.448~458 (2005)
- Kasper S, "Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder : a randomized, double-blind comparison with sertraline", J Clin Psychiatry, 71, pp.109~120 (2010)
- Stein DJ, "Efficacy of agomelatine in generalized anxiety disorder : a randomized, double-blind, placebo-controlled study", J Clin Psychopharmacol, 28, pp.561~566 (2008)
- Stein DJ, "Agomelatine prevents relapse in generalized anxiety disorder : a 6-month randomized, double-blind, placebo-controlled discontinuation study", J Clin Psychiatry, 73, pp.1002~1008 (2012)
- Stanley C. Igwe, "Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials", Clinical Psychopharmacology and Neuroscience, 16(3), pp.235~245 (2018), 대한정신약물학회[DOI]
- Wang SM, "Modafinil for the treatment of attention-deficit", hyperactivity disorder : a meta-analysis, 2017, pp.84, 292~300
- Cheung MW, "A guide to conducting a meta-analysis", Neuropsychol Rev, 26, pp.121~128 (2016)
- Demyttenaere K, "Agomelatine in treating generalized anxiety disorder", Expert Opin Investig Drugs, 23, pp.857~864 (2014)
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Nakagawa S, "Meta-evaluation of meta-analysis : ten appraisal questions for biologists", BMC Biol, 15, pp.18~ (2017)
- Melsen WG, "The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses", Clin Microbiol Infect, 20, pp.123~129 (2014)
- von Hippel PT, "The heterogeneity statistic I2 can be biased in small meta-analyses", BMC Med Res Methodol, 15, pp.35~ (2015)
- Brockwell SE, "A comparison of statistical methods for meta-analysis", Stat Med, 20, pp.825~840 (2001)
- Stein DJ, "Agomelatine in generalized anxiety disorder : an active comparator and placebo-controlled study", J Clin Psychiatry, 75, pp.362~368 (2014)
- Stein DJ, "Efficacy and safety of agomelatine(10 or 25mg", day)in non-depressed out-patients with generalized anxiety disorder : A 12-week, double-blind, placebo-controlled study, 2017, pp.27, 526~537
- Altman DG, "Meta-analysis, Simpson’s paradox, and the number needed to treat", BMC Med Res Methodol, 2, pp.3~ (2002)
- Citrome L, "When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed", Int J Clin Pract, 67, pp.407~411 (2013)
- Reinhold JA, "Pharmacological treatment for generalized anxiety disorder in adults : an update", Expert Opin Pharmacother, 16, pp.1669~1681 (2015)
- Wood MD, "Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders", Curr Drug Targets CNS Neurol Disord, 2, pp.383~387 (2003)
- Faraone SV, "Interpreting estimates of treatment effects : implications for managed care", P&T, 33, pp.700~711 (2008)
- Hidalgo RB, "An effect-size analysis of pharmacologic treatments for generalized anxiety disorder", J Psychopharmacol, 21, pp.864~872 (2007)
- Taylor D, "Antidepressant efficacy of agomelatine : meta-analysis of published and unpublished studies", BMJ, 348, pp.g1888~ (2014)
- Huang KL, "Comparison of agomelatine and selective serotonin reuptake inhibitors", serotonin-norepinephrine reuptake inhibitors in major depressive disorder : a meta-analysis of head-to-head randomized clinical trials, 2014, pp.48, 663~671
- Freiesleben SD, "A systematic review of agomelatine-induced liver injury", J Mol Psychiatry, 3, pp.4~ (2015)
- Lundh A, "Industry sponsorship and research outcome : systematic review with meta-analysis", Intensive Care Med, 44, pp.1603~1612 (2018)
- Bero L, "Industry sponsorship and research outcome : a Cochrane review", JAMA Intern Med, 173, pp.580~581 (2013)